(Q83168633)

English

Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis

scientific article published on 29 March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

cutaneous leishmaniasis

1 reference

based on heuristic

inferred from title

mucocutaneous leishmaniasis

1 reference

based on heuristic

inferred from title

Leishmania amazonensis

object named as

Leishmania amazonensis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Manuel Calvopiña

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Paola A Barroso

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jorge D Marco

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Masataka Korenaga

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Philip J Cooper

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Shigeo Nonaka

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Yoshihisa Hashiguchi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

29 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

27-28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

5645-5652

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Leishmaniasis: current status of vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Therapy of murine cutaneous leishmaniasis by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Second-generation vaccines against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

The immunology of Leishmania infection and the implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Restoration of immune responses in tumor-bearing mice by ONO-4007, an antitumor lipid A derivative

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Toll-like receptors as adjuvant receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Inhibition of intracellular proliferation of Leishmania parasites in vitro and suppression of skin lesion development in BALB/c mice by a novel lipid A analog (ONO-4007).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Human cutaneous lieshmania in a mouse macrophage line: propagation and isolation of intracellular parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Humoral immune responses among mucosal and cutaneous leishmaniasis patients caused by Leishmania braziliensis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Protection of C3HeB/FeJ mice against Leishmania amazonensis challenge after previous Leishmania major infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Targeting the innate immune response with improved vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Taking toll: lipid A mimetics as adjuvants and immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

TGF-beta-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

IFN-beta and TGF-beta differentially regulate IL-12 activity in human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Lipid A analogue, ONO-4007, inhibits IgE response and antigen-induced eosinophilic recruitment into airways in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

Role of inorganic nitrogen oxides and tumor necrosis factor alpha in killing Leishmania donovani amastigotes in gamma interferon-lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.023

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.03.023

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16621179%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83168633&oldid=1984636015"